1 proval: azilsartan medoxomil (6), olmesartan medoxomil (20), and ceftobiprole medocaril (29), and one

2 ee prodrugs gaining FDA approval: azilsartan medoxomil (6), olmesartan medoxomil (20), and ceftobipro

3 potassium, irbesartan, valsartan, olmesartan medoxomil, and telmisartan.

4                                   Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this int

5  which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients

6                                The faropenem medoxomil optimal dosage was 30 mg/kg 3-4 times daily.

7 tive analyzes the history and application of medoxomil prodrugs and discusses their potential for dru

8                                 Among these, medoxomil promoieties have been judiciously employed in